Cancer Treatment In India Is Changing — Here Is What Patients And Families Need To Know In 2026

By Author: adsmagnify
Total Articles: 11
Comment this article

Advanced cancer therapies like CAR T-cell therapy and immunotherapy are now available in India. Here is a clear, straightforward guide to what these treatments are, who they are designed for, and how the landscape has changed.

For years, the options for cancer treatment in India were formulas that everyone knew—surgery, radiation, and chemotherapy. They are still useful. But two to three years ago, something changed, and it is something every patient, caregiver, and family dealing with a cancer diagnosis needs to understand.

Cancer therapies such as immunotherapy, targeted therapy, and cellular treatments like CAR T-cell therapy are now available in India in a way that was not necessarily possible earlier. Learning what these treatments mean, what they are designed to do, and when they may be applicable is very important for any family dealing with a cancer diagnosis.

The Treatment Landscape Is Changing

CAR T-cell therapy is improving rapidly. By 2026, it is safer, more effective, and reaching more patients than ever before. Researchers have discovered ways to minimise severe side ...
... effects, reduce treatment timelines, and achieve breakthroughs that make CAR T-cell therapy effective against more types of cancer. New generations of CAR T cells are living longer in the body and are much better at attacking cancer cells without harming healthy cells.

This is not a minor upgrade. It is a fundamental change in what is possible for patients who are not responding well to conventional treatment.

India's healthcare landscape is also changing with the approval of cutting-edge CAR T-cell therapies, offering new hope for more than 120,000 blood cancer patients diagnosed in the country every year. India now has its own approved and available CAR T-cell therapy, placing the country in genuine participation in the global next-generation oncology market rather than simply being a destination for older-generation treatment options.

What CAR T-Cell Therapy Really Is

The name sounds complicated, and the science behind it is truly advanced, but the underlying concept is simple.

CAR T-cell therapy involves taking T cells from a patient, modifying them in a laboratory, and then infusing them back into the patient.

T cells are a type of white blood cell that serve as frontline warriors in the body's defence system. They travel through the bloodstream looking for signs of infection or abnormal cells, such as cancer cells. Once they detect something suspicious, they attack directly and also signal other immune cells to support the response.

CAR T-cell therapy essentially upgrades this natural process, giving the immune system a much sharper and more effective set of instructions to identify and attack cancer cells.

The CAR T process is a five-step procedure: T-cell collection, genetic modification, laboratory expansion, pre-treatment chemotherapy, and cell reinfusion. The entire process takes several weeks from start to finish and requires specialised facilities with the infrastructure needed to safely support cellular therapy.

What Are Immunotherapy and Targeted Therapy?

The oncology landscape has undergone rapid change in recent years, with two other areas significantly transforming cancer treatment.

Immunotherapy is an umbrella term that covers a range of biologic agents that help the body's immune system more effectively recognise and destroy cancer cells. Rather than targeting cancer directly, as chemotherapy does, immunotherapy modifies the environment in which the immune system functions, eliminating factors that allow cancer cells to hide.

Targeted therapy takes a different approach.

It uses drugs specifically engineered to target molecular alterations responsible for the growth of certain cancers. Rather than indiscriminately destroying rapidly dividing cells, targeted therapy focuses on the characteristics driving the cancer. This makes it effective in some cases that do not respond to conventional chemotherapy and also results in a different side-effect profile.

Both targeted therapy and immunotherapy have expanded treatment options for patients whose cancers have not responded to conventional therapies or for whom conventional treatments involve significant risks.

Who These Treatments Are Relevant For

This is an important question, and one that deserves an honest answer rather than broad reassurance.

At present, advanced therapies such as CAR T-cell treatment are most established for specific blood cancers, including certain types of leukemia, lymphoma, and multiple myeloma. Researchers are also actively exploring how CAR T cells may help treat solid tumours, but the strongest evidence currently exists in blood cancers.

By 2026, professionally manufactured CAR T cells created from healthy donors and stored until needed are showing promising early results. Improved bridging treatments are helping keep cancer under control while CAR T cells are being manufactured, easing the burden on patients and their families. Reduced treatment timelines minimise delays and increase the likelihood of successful outcomes.

The applicability of immunotherapy and targeted therapy is broader across different cancer types. However, the specific treatment approach must be evaluated by oncologists specialising in these therapies based on a patient's diagnosis, molecular characteristics, overall health, and previous treatments.

Determining whether any of these therapies is appropriate requires assessment by an oncologist experienced in these treatments rather than relying solely on general information or online searches.

Why Access to Specialised Centres Matters

Not all oncology facilities possess the infrastructure, sterile controlled environments, isolation facilities, trained clinical teams, and diagnostic capabilities required to successfully implement advanced therapies and support patients.

These therapies demand specialised infrastructure, sterile controlled environments, isolation facilities, trained clinical teams, and advanced diagnostic capabilities. Ongoing and planned studies continue to confirm the efficacy and safety of these therapies, but only in facilities equipped to safely administer and manage these novel treatment approaches.

Timing is critical. Patients considering CAR T-cell therapy should ideally be evaluated before becoming too weak after multiple failed treatments. Choosing the right facility—one with genuine experience in successfully delivering these therapies, not merely knowledge of them—is among the most important decisions a patient and family will face.

SunAct (sunactcancer.com) is a specialised oncology centre in India dedicated to advanced cancer therapies, including CAR T-cell therapy, bone marrow and stem cell transplantation, immunotherapy, and targeted therapy. The centre brings together oncologists with decades of research and clinical experience in these areas, with work published in top-tier international journals.

SunAct was purposefully designed to deliver these therapies, with isolation rooms, sterile controlled environments, and the infrastructure required for advanced cellular therapies.